Whole-surgical-field preparation protocol — preoperative bathing, hair removal practice, antiseptic selection, application technique, and special-site considerations
Before any antiseptic is ever opened in the operating room, the patient's own skin flora has already been shaped by a simple, low-cost intervention: a preoperative shower or bath. Whole-body cutaneous microbial density can be meaningfully reduced by instructing patients to wash with an antiseptic agent (most commonly 4% chlorhexidine gluconate) or, at minimum, plain soap, the night before and again the morning of surgery. This is not a substitute for intraoperative skin antisepsis — it is a bioburden-reduction step that makes the subsequent surgical-field prep more effective.
Human skin is never sterile. Resident flora (coagulase-negative staphylococci, Cutibacterium acnes, corynebacteria) live in hair follicles and sebaceous glands, while transient flora (picked up from clothing, bedding, environmental contact) sit more superficially. Both contribute to the total bioburden an intraoperative antiseptic must reduce in the few minutes available before incision.
Preoperative bathing does three things:
1. Mechanically removes loose debris, desquamated skin cells, and superficial transient flora through friction and rinsing. 2. When an antiseptic agent (CHG) is used, leaves a substantivity layer bound to the stratum corneum that continues suppressing bacterial regrowth for hours after the shower. 3. Reduces the "starting line" bioburden so that the brief intraoperative prep — which only has a few minutes of contact time — has less work to do and a higher probability of reaching an adequately low residual colony count at incision.
Studies quantifying CFU/cm² before and after a single CHG shower show reductions of roughly 9-fold; the effect compounds with a second, same-day wash, though evidence for reduction in actual surgical site infection (SSI) rates from bathing alone (independent of intraoperative prep) is more modest and mixed across trials.
Typical preoperative bathing protocols specify:
• Night-before shower: full-body wash with 4% CHG solution or CHG-impregnated cloths, with attention to the anticipated surgical site and adjacent skin folds. • Morning-of shower: a second wash, sometimes with a lower-concentration CHG product, performed as close to arrival at the facility as practical. • Hair washing: normal shampoo is acceptable; CHG is not typically applied to the scalp or near mucous membranes. • Clear instructions: patients are told to avoid lotions, powders, or deodorants after washing, since these can interfere with antiseptic residual activity at the surgical site. • Documentation: many institutions use a checklist or nursing note confirming bathing compliance was reviewed with the patient preoperatively.
When CHG is contraindicated (known allergy, use near eyes/ears/genital mucosa) or unavailable, plain antibacterial or even plain soap and water washing remains an acceptable and still beneficial alternative — mechanical removal of debris and transient flora has value on its own, even without a persistent antiseptic residue.
Preoperative bathing is a bioburden-reduction step, not a replacement for intraoperative surgical-field antisepsis. Even a well-washed patient still requires full antiseptic skin preparation immediately before incision — the shower simply gives that preparation a cleaner starting point.
For most of the 20th century, preoperative shaving with a razor was routine. Decades of accumulated evidence changed that: razors create microscopic breaks in the epidermis that bacteria rapidly colonize, measurably raising surgical site infection risk compared with clipping or leaving hair in place. Modern guidelines converge on a simple hierarchy — avoid hair removal when possible; if removal is necessary, clip immediately before surgery; never shave.
A razor blade does not simply remove hair — it drags a sharp edge across the stratum corneum, and even careful technique produces a field of microscopic nicks and superficial lacerations invisible to the naked eye. These micro-wounds:
• Breach the intact epidermal barrier that normally excludes bacteria. • Provide a moist, nutrient-rich micro-environment (serum, disrupted keratinocytes) that resident and transient skin flora colonize rapidly — colonization increases measurably within just a few hours of shaving. • Are numerous enough across a shaved field that antiseptic contact alone cannot reliably sterilize every breach point before incision.
The risk compounds with time between shaving and incision: hair removed the night before surgery gives colonizing bacteria far longer to establish themselves in the micro-wounds than hair removed immediately before the patient enters the operating room. This is why "shaving the night before" was identified early as an especially high-risk practice and was among the first specific practices guidelines moved to eliminate.
Electric clippers with a disposable single-use head cut hair close to the skin surface without dragging a blade against it, avoiding the epidermal breach that razors cause. Correct clipping practice:
• Performed immediately before the patient enters the OR, or in the OR itself, not the night before. • Uses single-patient-use clipper heads (or heads disinfected between uses) to avoid cross-contamination. • Removes only the hair that would otherwise interfere with incision placement, wound closure, or dressing adhesion — not a wide margin "just in case."
The strongest evidence-based position, however, is simpler still: if hair at the surgical site will not interfere with the procedure, do not remove it at all. Hair itself is not a significant source of SSI when left undisturbed, and eliminating the removal step eliminates the microabrasion risk entirely. Removal should be reserved for cases where hair genuinely obstructs visualization, instrumentation, or wound closure.
Cochrane systematic reviews comparing hair removal methods found no evidence that shaving reduces SSI risk compared with clipping or no hair removal — and consistent evidence that shaving, particularly when performed well before surgery, increases it. This shifted "clip, don't shave — and only if needed" from a preference to a guideline-level standard of care.
The two dominant families of surgical-field antiseptics — alcohol-based chlorhexidine gluconate (CHG) preparations and povidone-iodine (PVI) — differ in speed of action, depth of kill, and how long their antimicrobial effect persists on skin after application. For most surgical sites on intact skin, current evidence and guidelines favor CHG-alcohol; for mucous membranes and certain other anatomic exceptions, iodine-based agents remain the appropriate — often the only acceptable — choice.
Chlorhexidine gluconate (CHG), typically formulated at 2% in 70% isopropyl alcohol, kills through two combined mechanisms: the alcohol carrier produces rapid, broad-spectrum microbial kill through protein denaturation, while the chlorhexidine molecule binds electrostatically to the negatively charged bacterial cell membrane, disrupting it and — critically — binds to the stratum corneum itself, creating a substantive antimicrobial residue that continues suppressing bacterial regrowth for several hours after application.
Povidone-iodine (PVI) works by releasing free iodine, which oxidizes microbial proteins, nucleotides, and fatty acids. It is fast-acting and broad-spectrum, but its activity is substantially reduced by the presence of organic material (blood, serum) and it lacks the same skin-binding persistence — once wiped or washed away, its antimicrobial effect is largely gone, whereas CHG continues working.
The landmark Darouiche et al. (NEJM, 2010) randomized trial directly comparing CHG-alcohol to aqueous PVI in clean-contaminated surgery found a large, statistically significant reduction in overall SSI with CHG-alcohol (9.5%) versus PVI (16.1%) — a result that shifted many institutions' default surgical-site antiseptic to CHG-alcohol.
Despite CHG-alcohol's general superiority on intact skin, PVI (usually as an aqueous, non-alcohol formulation) remains appropriate — and often necessary — for:
• Mucous membranes: vaginal, oral, and other mucosal surfaces, where alcohol-based CHG is irritating and CHG's safety profile on mucosa is less established. • Ocular and periocular surgery: alcohol-based preparations risk chemical keratitis; dilute aqueous PVI is the standard ophthalmic surgical antiseptic. • Middle ear / tympanic membrane exposure: CHG is ototoxic if it contacts the inner ear through a perforated tympanic membrane; PVI or saline-based alternatives are used instead. • Neonates and very young infants: thinner, more permeable skin increases systemic absorption risk and local irritation/chemical burn risk from concentrated CHG-alcohol; many protocols favor lower-concentration or aqueous alternatives. • CHG allergy: a documented (though uncommon) hypersensitivity requires switching to an iodine-based or alternative agent entirely.
Site selection is therefore not simply "always use CHG" — it is choosing the higher-performing agent as the default for most surgical fields while recognizing the specific anatomic and patient-population exceptions where it must be avoided.
Flammability is a practical corollary of CHG-alcohol's effectiveness: the same alcohol carrier that drives its rapid kill is also a fire hazard in the presence of electrocautery or laser if the antiseptic has not fully evaporated before draping. Agent selection and application technique are inseparable safety decisions.
Selecting the right antiseptic accomplishes little if it is applied incorrectly. Proper technique starts at the planned incision site and moves outward in a widening, non-retracing pattern, covering a margin wide enough to accommodate unexpected incision extension and drape placement — and then, critically, the antiseptic must be given time to fully air-dry before drapes are applied or electrocautery is activated.
Surgical-field antiseptic is applied starting at the intended incision site and worked outward toward the periphery of the prepped field, using a sponge, applicator, or single-use CHG-alcohol wand. The applicator is never brought back toward the incision site after having touched more peripheral, less-clean skin — this "clean to dirty, never back again" direction principle prevents re-contaminating the highest-priority zone (the incision line itself) with flora from the periphery.
Coverage must extend to a wide margin beyond:
• The anticipated incision, accounting for possible intraoperative extension. • The planned drape edges, so that any small drape shift during the case still exposes only prepped skin. • Areas that will be accessed for additional instrumentation, drains, or extension incisions (e.g., a separate port site).
For irregular or high-risk sites (umbilicus, skin folds, stomas), additional attention and sometimes a secondary application step are used to ensure the antiseptic reaches recessed or occluded skin that a single wipe may miss.
Alcohol-based antiseptics are only fully effective, and only safe, once they have completely air-dried. Manufacturer instructions for most CHG-alcohol products specify approximately 3 minutes of dry time on relatively hairless, flat skin, and longer on hair-bearing areas, skin folds, or when larger volumes have pooled.
Draping or activating an ignition source (electrocautery, laser, fiber-optic light source) before the antiseptic is fully dry creates two distinct hazards:
1. Surgical fire risk: residual alcohol vapor or pooled liquid trapped under drapes is a documented ignition source in operating-room fire events — flammable-prep-related fires are a recognized, preventable category of surgical fire in patient-safety literature. 2. Reduced antimicrobial reliability: an antiseptic that has not finished its evaporative/binding phase may not have reached its full residual antimicrobial state, undermining the very purpose of the prep.
Because of this, "confirm the prep is dry" is treated as a discrete, verifiable checklist item — not an assumption — in most modern surgical safety checklists, timed and visually confirmed before drape placement proceeds.
Pooling is the specific hazard to actively prevent: antiseptic that collects under the patient, in skin folds, around tourniquets, or in the umbilicus can remain wet far longer than the stated dry time and is a recognized cause of both chemical skin burns and surgical fires. Excess solution should be wicked away, not left to pool, during application.
The general protocol of CHG-alcohol, applied outward with full dry time, is the right default for most surgical fields — but several anatomic sites and patient populations require a deliberately different antiseptic choice or technique to avoid tissue toxicity that would outweigh any antimicrobial benefit.
Certain tissues lack the protective, relatively impermeable stratum corneum that makes CHG-alcohol both effective and well tolerated on typical skin, so contact there produces injury rather than safe antisepsis:
• Eyes and periocular tissue: alcohol-based CHG can cause chemical keratitis and conjunctival injury on contact; dilute aqueous povidone-iodine is the standard for ophthalmic surgical prep instead, applied with care to avoid pooling in the conjunctival fornix. • Middle ear / mastoid procedures with a perforated or absent tympanic membrane: CHG has documented ototoxicity if it reaches the inner ear structures, so otologic teams substitute non-ototoxic agents (e.g., specific PVI protocols or saline irrigation) when a perforation is known or suspected preoperatively. • Oral, vaginal, and other mucous membranes: thinner, more absorptive, and more sensitive than keratinized skin; aqueous PVI or mucosa-appropriate antiseptics are preferred over alcohol-based CHG.
Beyond specific anatomic tissues, certain patient populations and procedural setups create their own special-site logic:
• Neonates and young infants: skin is thinner, less keratinized, and more absorptive than adult skin, raising concern for both local chemical burns and systemic absorption of antiseptic agents. Many neonatal protocols use lower-concentration CHG, shorter contact/drying confirmation, or alternative agents, and take particular care to avoid pooling given fragile skin integrity. • Tourniquet and dependent-limb sites: antiseptic that pools beneath a limb tourniquet or in a dependent position (rather than evaporating normally) can sit against skin far longer than intended, causing chemical burns under the tourniquet cuff — a recognized, preventable complication requiring active wicking/blotting of excess solution before tourniquet inflation and draping. • Skin folds, stomas, and open wounds: recessed or already-compromised skin may need a secondary or modified application approach, and antiseptic choice may shift toward agents with a better-established safety profile on non-intact skin.
Across all of these exceptions, the underlying decision logic is the same as everywhere else in the protocol: match the antiseptic and technique to the specific tissue being prepped, rather than applying one universal solution to every anatomic site.
The special-site exceptions are not a footnote to the CHG-alcohol default — they are an integral part of a safe protocol. A prep team that reflexively reaches for standard CHG-alcohol without checking for ocular, mucosal, otologic, neonatal, or pooling-risk considerations converts an evidence-based best practice into a preventable harm.